more

Moderna (MRNA)

(Delayed Data from NSDQ)

$107.97 USD

+1.79 (1.69%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $107.85 -0.12 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can Biotech ETFs Continue to Soar in 2020?

by Neena Mishra Published on February 06,2020

We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.

etf
etfs

Should Growth Investors Buy this Cancer Screening Biotech Stock?

by Benjamin Rains Published on February 04,2020

Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research Published on February 03,2020

Moderna (MRNA) closed at $20.38 in the latest trading session, marking a -0.63% move from the prior day.

MRNAPositive Net Change

J&J (JNJ) Plans to Develop Vaccine for New Coronavirus

by Zacks Equity Research Published on January 30,2020

J&J (JNJ) is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.

pharmaceuticals

Coronavirus: How Fast to 100,000 Infected?

by Kevin Cook Published on January 30,2020

The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

Coronavirus: Epidemic or Pandemic?

by Kevin Cook Published on January 29,2020

The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

Implied Volatility Surging for Moderna (MRNA) Stock Options

by Zacks Equity Research Published on January 29,2020

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

MRNAPositive Net Change

biotechs

Wining & Losing ETF Areas on Coronavirus Outbreak

by Sanghamitra Saha Published on January 28,2020

Coronavirus outbreak puts these ETF areas in winning and losing positions.

etfs

Coronavirus Spooks Global Markets: Winners and Losers

by Zacks Equity Research Published on January 24,2020

So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.

CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs

by Indrajit Bandyopadhyay Published on January 24,2020

Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.

Company News for Jan 23, 2020

by Zacks Equity Research Published on January 23,2020

Companies in the news are: FSB, AKCA, ALLY, MRNA

3 Biotech Stocks Likely to Gain as Coronavirus Spreads

by Zacks Equity Research Published on January 23,2020

Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.

Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on January 22,2020

Is (MRNA) Outperforming Other Medical Stocks This Year?

MRNAPositive Net Change

5 Biotech Stocks Set for Continued Rally in 2020

by Zacks Equity Research Published on December 16,2019

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

biotechs

The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target

by Zacks Equity Research Published on November 25,2019

The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target

retail

5 Top Stocks That Surged Amid Volatility in the Last 7 Days

by Nalak Das Published on November 22,2019

Volatility has gripped Wall Street since the past week owing to several conflicting news about the signing of an interim trade deal between the United States and China.